Seaport Therapeutics, Inc. Common Stock (SPTX) - Net Assets
Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore investment intensity of Seaport Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Seaport Therapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Seaport Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See how many days can Seaport Therapeutics, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. For live valuation and market cap data, see Seaport Therapeutics, Inc. Common Stock (SPTX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-92.55 Million | -272.43% |
| 2024-12-31 | $-24.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seaport Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7488100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.56 Million | % |
| Total Equity | $-92.55 Million | 100.00% |
Seaport Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chengdu Kanghua Biological Products
SHE:300841
|
$871.85 Million |
|
Focused Photonics Hangzhou Inc
SHE:300203
|
$872.02 Million |
|
indie Semiconductor Inc
NASDAQ:INDI
|
$872.62 Million |
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
$872.63 Million |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
$871.72 Million |
|
Appotronics Corp Ltd
SHG:688007
|
$871.64 Million |
|
Seneca Foods Corp A
NASDAQ:SENEA
|
$871.48 Million |
|
Shenzhen Fuanna Bedding and Furnishing Co Ltd
SHE:002327
|
$870.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seaport Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -24,849,000 to -92,545,000, a change of -67,696,000.
- Net loss of 74,881,000 reduced equity.
- Other factors increased equity by 7,185,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.88 Million | -80.91% |
| Other Changes | $7.18 Million | +7.76% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Seaport Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-0.47 | $17.44 | x |
| 2025-12-31 | $-1.75 | $17.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seaport Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-44.39 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.63 Million |
Industry Comparison
This section compares Seaport Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,937,365
- Average return on equity (ROE) among peers: -92.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $- | 0.00% | N/A | $871.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.61 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $322.52 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-6.52 Million | 0.00% | 0.00x | $32.76 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.83 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $3.64 Billion |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce l… Read more